All News

Level, monitor, calculate, glucose, diabetes

Metabolic Syndrome Predicts Cardiovascular Outcomes in Inflammatory Arthritis

Jack Cush, MD

Chronic inflammatory arthritis (CIA) is associated with elevated cardiovascular risk. While metabolic syndrome (MetS) is prevalent, how much it contributes to adverse clinical outcomes is unclear.

Read Article
morbidity,covid,heart,lung,brain

More Comorbidity in Difficult to Treat RA

Jack Cush, MD

A systematic review demonstrated that smoking, obesity, fibromyalgia, and depression are significantly associated with difficult-to-treat rheumatoid arthritis (D2T-RA).

Read Article
virus,injection,COVID,vaccine

COVID Virus Persistence with DMARD Use

MedPage Today

Drugs commonly used to treat systemic autoimmune rheumatic diseases (SARDs) may keep the SARS-CoV-2 circulating after COVID-19 infection in patients with these conditions, with researchers documenting substantially increased viral antigen persistence compared with other post-COVID patients.

Read Article
obesity.back_.jpg

Review of GLP-1 Receptor Agonists in Psoriasis

Jack Cush, MD

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed cardiometabolic medicine and are now attracting intense interest in inflammatory disorders.

Read Article
Tavneos

FDA Targeting the Safety of Avacopan

Jack Cush, MD

The future of avacopan is up in the air. In April, the FDA issued a drug safety warning, previously requesting that Amgen to pull its rare disease drug Tavneos from the market. Now, there appears more pressure to remove it from the market.

Read Article
exercise,group

EULAR Recommendations for Physical Activity in Arthritis

Jack Cush, MD

EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA). 

Read Article
38420215_s.jpg

Neoplasia and Autoimmune Disease

Jack Cush, MD

Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune phenomena (paraneoplastic syndromes, checkpoint inhibitor-induced rheumatic disease).

Read Article
choices2.jpg

Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA

Jack Cush, MD

After the first tumour necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab.

Read Article
RheumNow Podcast square

Follow the Money (4.23.2026)

Jack Cush, MD

Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week. 

Read Article
Steroids Corticosteroids remain a cornerstone of rheumatologic therapy — rapidly effective but chronically dangerous, as their power to suppress inflammation through inhibition of prostaglandins, lipoxygenase, pro-inflammatory cytokines, and proteases comes at the cost of a https://t.co/fKGgYF3yWA
Dr. John Cush RheumNow ( View Tweet)
RCT 120 mod-severe hip OA (KL 2-4) pts Rx w/ THA +rehab or exercise. @12 mos. THA had signif. better pain, function & HRQoL vs exercise program alone (WOMAC total -30.9 vs -3.7). (38% of exercise/conservative grp needed THA) https://t.co/6vvRAr6isf https://t.co/VOYgS3PPwr

Links:

Dr. John Cush RheumNow ( View Tweet)
Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://t.co/AmG6hkWABW https://t.co/MYhkfxAh0r

Links:

Dr. John Cush RheumNow ( View Tweet)
True or False: In a meta-analysis, RA was associated with a significantly increased risk of osteoporotic fractures in female patients but not in male patients. See if you got it right in the latest RheumIQ quiz at https://t.co/HCxOwRl2Tq. https://t.co/O9WRKQKmu4

Links:

Dr. John Cush RheumNow ( View Tweet)
Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA After the first tumor necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab. https://t.co/Cml3Z7ZyQP
Dr. John Cush RheumNow ( View Tweet)
Prospective study of 305 Consecutive newly diagnosed axSpA pts (55% male; Dx delay 6 yrs; 75% B27+). 56% w/ r-axSpA more male w/ hi CRP. nr-axSpA had more inflam LBP, +FHx SpA. SpA Dx made without sacroiliitis in 12%; only 2/38 later developed sacroiliitis https://t.co/xPlGwZ7Kjk https://t.co/2TBQALvxsG

Links:

Dr. John Cush RheumNow ( View Tweet)
True or False: Low-dose aspirin given at giant cell arteritis diagnosis is associated with a lower risk of major adverse cardiovascular events. Put your answer to the test in the latest RheumIQ quiz at https://t.co/XLPVoyCbLB. https://t.co/C5CSwuv5mF

Links:

Dr. John Cush RheumNow ( View Tweet)
Arthralgia w/ HIGH ACPA level >3x ULN) has a 30–50% probability of being diagnosed with RA within 3–5 years https://t.co/iJTyMQM480

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatology Salaries 2025 Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum. https://t.co/DNe42EsxRW https://t.co/aegcNm8Pla

Links:

Dr. John Cush RheumNow ( View Tweet)
Does monotherapy work? network meta-analysis of 31 RCTs, 13 csDMARDs, Leflunomide, SSZ & gold were better than placebo & equal to MTX regarding annual xray progression scores. Evidence in favor BUT failed to study monoRx vs Combo Rx https://t.co/cMSZ4QHi5G https://t.co/o9ikhJu3UM

Links:

Dr. John Cush RheumNow ( View Tweet)
Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Elena Myasoedova examines mortality trends in RA, exploring whether we are seeing continued decline, delayed impact, or a concerning https://t.co/yUob3Tv0tR

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×